Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 2,339 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all
Completed Phase 1 Interventional

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

NCT04857606
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
AMG 609, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Chandler, Arizona • Chula Vista, California • Montclair, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 17, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

NCT06878248
View directory record Official record
Conditions
Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC), Hormone Receptor-Positive Breast Cancer, HER2 + Breast Cancer
Interventions
Two Component Product CLBR001 + ABBV-461
Biological
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Augusta, Georgia • Indianapolis, Indiana • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Results available

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CVX-096
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Miami Gardens, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 17, 2026, 9:39 AM EDT
Not listed Phase 4 Interventional

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
6 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Gainesville, Florida • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 17, 2026, 9:39 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

NCT07416526
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007, Human Coagulation Factor VIII
Combination Product · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Aurora, Colorado • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

NCT02616185
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
PF-06755992, PF-06755990, TDS-IM Electroporation Device, Tremelimumab, PF-06801591, PF-06753512
Biological · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
19
States / cities
Tucson, Arizona • New Haven, Connecticut • Bethesda, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

NCT00976599
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 + methotrexate, Placebo + Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Frederick, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

NCT00914667
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
warfarin, Warfarin plus Fesoterodine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

NCT02766634
View directory record Official record
Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
Filgrastim Hospira (US), U.S.-approved Neupogen®
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 17, 2026, 9:39 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493
View directory record Official record
Conditions
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
Drug · Combination Product
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
57
States / cities
Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

NCT01497600
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin NPH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 17, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

NCT07734493
View directory record Official record
Conditions
Schizophrenia
Interventions
LTX-001 once daily, Placebo, LTX-001 twice daily
Drug
Lead sponsor
Leal Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Alamitos, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

NCT03556007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Tranexamic Acid Pharmacokinetics During Postpartum Hemorrhage

NCT03863964
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
blood test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

NCT01692184
View directory record Official record
Conditions
Healthy
Interventions
50 mg AVL-292, 100 mg AVL-292, 200 mg AVL-292, 350 mg AVL-292, Placebo capsules
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

NCT05518734
View directory record Official record
Conditions
Pain
Interventions
VX-708, Itraconazole, Midazolam, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 17, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

NCT05233436
View directory record Official record
Conditions
Advanced Solid Tumors, Gastric Cancer, Gastroesophageal Junction Cancer, Urothelial Cancer, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinomas
Interventions
PF-07265028, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study in Japanese Subjects

NCT01872832
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 and Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 17, 2026, 9:39 AM EDT
Recruiting Phase 3 Interventional

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563
View directory record Official record
Conditions
IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

NCT03724292
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, VTP-43742
Drug
Lead sponsor
Vitae Pharmaceuticals Inc., an Allergan affiliate
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT00867932
View directory record Official record
Conditions
Hemoglobinuria, Paroxysmal
Interventions
Eculizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Orange, California • Pensacola, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

NCT02081014
View directory record Official record
Conditions
Hypoglycemia
Interventions
G-Pen Mini™ (glucagon injection)
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

NCT01284062
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Anrukinzumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 17, 2026, 9:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

NCT03347968
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MEDI0382, Warfarin, Esmolol
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 17, 2026, 9:39 AM EDT